BLSM: Lead EGFR inhibitor shows durable responses in resistant cancer, with pivotal milestones ahead
BlossomHill presented strong phase I data for its lead EGFR inhibitor, showing high response rates and durability in C797S-resistant patients, with a favorable safety profile and differentiation from competitors. Key milestones include pivotal trial planning and new data readouts through 2027.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.